MGMT and urinary bladder cancer: Glistoblastoma, TNBC (HER2+, TP53 mutations subtype); bladder cancer with high TMB subtypes, TP53, ERCC2 mutations; Glioblastomas with amplifications, PTEN loss, MGMT methylation